Loading...

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

PURPOSE: A phase II study was conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)–supplied agent investigational new drug No. 59,699) in patients with persistent or recurrent endometrial cancer who have progressed despite standard therapy. PATIENTS AN...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2009
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2716935/
https://ncbi.nlm.nih.gov/pubmed/19451430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6995
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!